YM155 sensitizes HeLa cells to TRAIL-mediated apoptosis via cFLIP and survivin downregulation

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy shows promise for cancer treatment but is less effective against cervical cancer.
• Survivin is a key protein that inhibits apoptosis and contributes to cancer cell survival.
• Cervical cancer often exhibits resistance to conventional TRAIL-induced apoptosis.

Purpose of the Study:

• To investigate the efficacy of a combination therapy using low-dose YM155 and TRAIL to overcome TRAIL resistance in cervical cancer cells.
• To elucidate the molecular mechanisms underlying the synergistic effect of YM155 and TRAIL in inducing apoptosis.
• To evaluate the impact of this combination therapy on cervical cancer cell viability, invasion, and migration.

Main Methods:

• HeLa cervical cancer cells were treated with TRAIL and/or low-dose YM155.
• Apoptosis was assessed using propidium iodide staining.
• DNA damage was evaluated by examining the phosphorylation of γH2A histone family member X via immunofluorescence and western blot.
• Expression levels of CASP8- and FADD-like apoptosis regulator (cFLIP), death receptor 5 (DR5), and survivin were analyzed using RT-PCR and western blot.

Main Results:

• TRAIL or YM155 alone did not significantly induce apoptosis or DNA damage.
• The combination of TRAIL and YM155 demonstrated a synergistic pro-apoptotic effect in HeLa cells.
• Combined treatment led to the downregulation of both mRNA and protein levels of cFLIP and survivin.
• The combination therapy significantly reduced cell viability, invasion, and migration.

Conclusions:

• Low-dose YM155 sensitizes cervical cancer cells to TRAIL-induced apoptosis.
• The synergistic effect is mediated by the downregulation of cFLIP and survivin.
• This combinatorial approach represents a potential therapeutic strategy for enhancing TRAIL efficacy in human cervical cancer.